REG - ValiRx PLC - Proposed Director Appointment

ValiRxAnnouncement

03/07/2024 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240703:nRSC9686Ua&default-theme=true

RNS Number : 9686U  ValiRx PLC  03 July 2024

3 July 2024

 

ValiRx PLC

 

("ValiRx" or the "Company")

 

Proposed Director Appointment

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, announces the proposed
appointment of Cathy Tralau-Stewart as an Executive Director of the Company,
subject to standard regulatory due diligence. Cathy is currently the Chief
Scientific Officer of the Company.

Cathy is a highly  experienced drug discovery pharmacologist who has led many
successful projects which have resulted in a number of marketed products and
many other clinical candidate molecules. She has led discovery projects, and
due diligence on over 500 early drug discovery projects in a wide range of
therapeutic areas.

Following her PhD in Clinical Sciences (Cancer therapeutics) at University
College London, Cathy worked in pre-clinical & early clinical drug
discovery at GSK. In 2007 she founded the Imperial College London Drug
Discovery Centre. In 2013 Cathy moved to the West Coast USA where she led The
UCSF catalyst translational program and was an Associate Professor of
Bioengineering & Therapeutic Sciences. Subsequently she joined Takeda
Pharmaceuticals in External Innovation (2018-2021), leading an extensive
network of academic alliances along the West Coast (UC San Diego, Stanford
University, The University of Washington & The Fred Hutch Cancer Centre,
Seattle). In 2021, Cathy returned to the UK and held Chief Scientific Officer
positions at C4X Discovery. Cathy is also Executive Director of The Milner
Therapeutics Institute, University of Cambridge.

A further announcement will be made in due course.

The Directors of the Company take responsibility for this announcement.

 

*** ENDS ***

For more information, please contact:

 

 ValiRx plc                                        Tel: +44 (0) 2476 796496

                                                   www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                             Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray/ Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAXXDELNLEEA